◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › P › PCRX

Pacira BioSciences, Inc. (PCRX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-17

Pacira BioSciences, Inc. (PCRX) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Brisbane, United States with about 825 employees. Its market capitalization is roughly $984 million. In the fiscal year ended 2025-12-31, PCRX reported $726M in revenue and $7M in net income.

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.

Interactive charts & full statements → Open the PCRX valuation workbench →

PCRX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Revenue	$746M	$726M	$701M	$675M	$667M	$542M	$430M	$421M	$337M	$287M	$276M	$249M	$198M	$86M	$39M	$16M	$15M	$15M	$14M
Gross Profit	$591M	$577M	$531M	$490M	$468M	$401M	$312M	$314M	$250M	$199M	$166M	$177M	$120M	$31M	$7M	($1M)	$2M	$3M	($4M)
Gross Margin %	79.2%	79.4%	75.7%	72.6%	70.1%	74.1%	72.7%	74.7%	74.2%	69.3%	60.2%	71.2%	60.8%	36.0%	17.8%	-6.7%	15.7%	18.0%	-25.4%
Operating Income (EBIT)	$18M	$33M	($73M)	$88M	$60M	$90M	$46M	$10M	$16M	($25M)	($32M)	$9M	($5M)	($53M)	($49M)	($39M)	($22M)	($29M)	($45M)
Operating Margin %	2.4%	4.6%	-10.5%	13.0%	9.0%	16.6%	10.8%	2.5%	4.7%	-8.7%	-11.6%	3.8%	-2.6%	-62.3%	-126.1%	-249.2%	-153.6%	-190.2%	-325.8%
Net Income	$15M	$7M	($100M)	$42M	$16M	$42M	$146M	($11M)	$0M	($43M)	($38M)	$2M	($14M)	($64M)	($52M)	($43M)	($27M)	($32M)	($42M)
Net Margin %	2.0%	1.0%	-14.2%	6.2%	2.4%	7.8%	33.9%	-2.6%	-0.1%	-14.9%	-13.7%	0.8%	-6.9%	-74.7%	-133.8%	-276.2%	-186.4%	-211.3%	-300.6%
EBITDA	$115M	$123M	$29M	$155M	$140M	$114M	$64M	$31M	$33M	($11M)	($18M)	$21M	$5M	($51M)	($45M)	($34M)	($19M)	($24M)	($42M)
Earnings Per Share (EPS)	$0.35	$0.16	$-2.15	$0.81	$0.34	$0.92	$3.33	$-0.27	$-0.01	$-1.07	$-1.02	$0.04	$-0.39	$-1.93	$-1.72	$-2.64	$-1.58	$-32.00	$-42.00
Shares Outstanding (M)	40M	45M	46M	52M	47M	46M	44M	42M	41M	40M	37M	41M	35M	33M	30M	16M	—	1M	1M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PCRX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$192M	$177M	$197M	$180M	$181M	$169M	$187M	$169M
Gross Profit	$148M	$141M	$157M	$145M	$140M	$135M	$147M	$130M
Gross Margin %	77.0%	79.5%	79.5%	80.9%	77.4%	79.7%	78.7%	77.0%
Operating Income (EBIT)	$4M	$5M	$3M	$6M	$8M	$2M	$25M	($140M)
Operating Margin %	2.2%	2.6%	1.6%	3.5%	4.7%	1.2%	13.2%	-82.8%
Net Income	$5M	$3M	$2M	$5M	($5M)	$5M	$16M	($143M)
Net Margin %	2.4%	1.6%	0.8%	3.0%	-2.7%	2.9%	8.6%	-85.1%
EBITDA	$26M	$30M	$25M	$34M	$29M	$34M	$51M	($115M)
Earnings Per Share (EPS)	$0.12	$0.07	$0.04	$0.12	$-0.11	$0.10	$0.33	$-3.11
Shares Outstanding (M)	40M	41M	43M	44M	45M	47M	49M	46M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PCRX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Cash from Operations (CFO)	$188M	$152M	$189M	$155M	$145M	$126M	$77M	$71M	$49M	$18M	$33M	$29M	$25M	($43M)	($70M)	($31M)	($25M)	($21M)	($29M)
Capital Expenditures (CapEx)	$8M	$15M	$11M	$15M	$30M	$46M	$38M	$10M	$15M	$19M	$25M	$41M	$22M	$13M	$18M	$6M	$7M	$6M	$6M
Free Cash Flow (FCF)	$179M	$137M	$179M	$139M	$115M	$80M	$39M	$60M	$34M	($1M)	$9M	($12M)	$4M	($56M)	($88M)	($37M)	($32M)	($26M)	($35M)
FCF Margin %	24.0%	18.8%	25.5%	20.7%	17.3%	14.8%	9.1%	14.3%	10.2%	-0.5%	3.2%	-4.9%	1.8%	-65.5%	-226.1%	-236.9%	-217.4%	-175.6%	-251.5%
Dividends Paid	—	—	—	$3M	—	$3M	$2M	$4M	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PCRX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$57M	$26M	$44M	$61M	$12M	$35M	$33M	$54M
Capital Expenditures (CapEx)	$1M	$3M	$0M	$4M	$3M	$9M	$2M	$4M
Free Cash Flow (FCF)	$56M	$23M	$43M	$57M	$9M	$27M	$31M	$50M
FCF Margin %	29.2%	12.9%	22.1%	31.7%	5.1%	15.9%	16.6%	29.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

PCRX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31
Total Assets	$1.2B	$1.3B	$1.6B	$1.6B	$1.7B	$2.1B	$1.3B	$831M	$689M	$628M	$391M	$390M	$326M	$170M	$112M	$113M	$67M	$44M	$51M
Cash & Cash Equivalents	$206M	$159M	$277M	$153M	$104M	$586M	$100M	$78M	$133M	$54M	$36M	$159M	$158M	$13M	$43M	$46M	$26M	$7M	$12M
Total Liabilities	$572M	$572M	$775M	$704M	$906M	$1.3B	$655M	$476M	$368M	$349M	$172M	$171M	$155M	$129M	$46M	$65M	$115M	$67M	$43M
Total Debt (Short + Long-Term)	$373M	$382M	$594M	$531M	$699M	$1.1B	$470M	$311M	$291M	$276M	$217M	$104M	$103M	$100M	$36M	$27M	$78M	$29M	$5M
Total Shareholders' Equity	$672M	$693M	$778M	$870M	$775M	$730M	$620M	$355M	$321M	$279M	$219M	$218M	$171M	$41M	$66M	$48M	($48M)	($23M)	$7M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PCRX viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

XERS · Xeris Pharmaceuticals Inc — $1 billion
PAHC · Phibro Animal Health Corporation — $1 billion
HROW · Harrow Health Inc — $1 billion
CRON · Cronos Group Inc — $1 billion
GLAS · Glass House Brands Inc. — $800 million
TAK · Takeda Pharmaceutical Co Ltd ADR — $60 billion
UTHR · United Therapeutics Corporation — $21 billion
NBIX · Neurocrine Biosciences Inc — $15 billion

← PCR All “P” companies PCS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.